Trial
NCT00748709
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Neoplasms
Intervention
BIBW 2992 (Afatinib)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-11